This protocol addresses patients with seminoma at stage IIB through III who meet the IGCCCG good prognosis criteria: no non-pulmonary visceral metastases, normal serum alpha-fetoprotein (AFP), and fitness for cisplatin-based chemotherapy.
Seminoma stage IIB–III · IGCCCG good prognosis classification · Normal serum AFP · No non-pulmonary visceral metastases · Any hCG level · Fit for cisplatin-based chemotherapy
Management in this setting involves high-dose chemotherapy — the complete regimen, cycle structure, and sequencing are detailed in the full protocol.
DOI: 10.1016/j.annonc.2022.01.002
Three cycles of BEP represents the standard therapy for seminoma patients categorised as good prognosis and four cycles of BEP for intermediate prognosis.
Cisplatin-based ChT according to the IGCCCG classification is standard for seminoma stage IIB-IIC and III.
HD-ChT should be employed in third-line therapy, if not already used earlier, and might still cure selected patients in this setting.
View source ↗